Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-IM)

PHASE3CompletedINTERVENTIONAL

Enrollment

407

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

January 31, 2011

Study Completion Date

August 31, 2011

Conditions

Osteoporosis

Interventions

DRUG

Parathyroid Hormone (PTH)

Self-administered (100 μg in a volume of 71.4 μL) daily as a subcutaneous injection in the abdomen using the Preotact pen.

DRUG

Risedronate

Orally once weekly as one 35 mg tablet.

Trial Locations (1)

Roskilde